Maternal Serum Placental Growth Factor Isoforms 1 and 2 at 11-13, 20-24 and 30-34 Weeks' Gestation in Late-Onset Pre-Eclampsia and Small for Gestational Age Neonates

2014 ◽  
Vol 35 (4) ◽  
pp. 249-257 ◽  
Author(s):  
Marta Nucci ◽  
Leona C. Poon ◽  
Gaiane Demirdjian ◽  
Bruno Darbouret ◽  
Kypros H. Nicolaides
Keyword(s):  
Growth Factor ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Late Onset ◽  
Maternal Serum ◽  
Placental Growth Factor

scholarly journals Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor

2005 ◽  
Vol 90 (8) ◽  
pp. 4895-4903 ◽  
Author(s):  
Eiji Shibata ◽  
Augustine Rajakumar ◽  
Robert W. Powers ◽  
Robert W. Larkin ◽  
Carol Gilmour ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Vascular Dysfunction ◽  
Normal Pregnancy ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Gestational Age At Delivery ◽  
Placental Protein

Context: An excess of the soluble receptor, fms-like tyrosine kinase 1 (sFlt-1) may contribute to maternal vascular dysfunction in women with preeclampsia by binding and thereby reducing concentrations of free vascular endothelial growth factor and placental growth factor (PlGF) in the circulation. The putative stimulus for increased sFlt-1 during preeclampsia, placental hypoxia due to poor perfusion, is common to both preeclampsia and idiopathic intrauterine growth restriction. However, the latter condition occurs without maternal vascular disease. Objective: We asked whether, as with preeclampsia, sFlt-1 is increased and free PlGF is decreased in villous placenta and maternal serum of normotensive women with small-for-gestational-age (SGA) neonates. Study Design: This was a case-control study using banked samples. Groups of women with SGA neonates (birth weight centile < 10th) and women with preeclampsia were matched to separate sets of normal pregnancy controls based on gestational age at blood sampling (serum) or gestational age at delivery (placenta). Results: sFlt-1 levels were higher in preeclamptics than controls (serum, P < 0.0001; placental protein, P = 0.03; placental mRNA, P = 0.007) but not increased in SGA pregnancies. PlGF was lower in both preeclampsia (serum, P < 0.0001; placental protein, P = 0.05) and SGA (serum, P = 0.0008; placental protein, P = 0.03) compared with their controls. PlGF in preeclampsia and SGA groups did not differ. Conclusions: These data are consistent with a role for sFlt-1 in the maternal manifestations of preeclampsia. In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in SGA pregnancies in the absence of a maternal syndrome.

Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11+0to 13+6weeks of gestation

2008 ◽  
Vol 28 (12) ◽  
pp. 1110-1115 ◽  
Author(s):  
Leona C. Y. Poon ◽  
Edgar Zaragoza ◽  
Ranjit Akolekar ◽  
Evangelos Anagnostopoulos ◽  
Kypros H. Nicolaides
Keyword(s):  
Growth Factor ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Maternal Serum ◽  
Placental Growth Factor

The association of serum placental growth factor with pregnancies complicated by preeclampsia and small for gestational age

2012 ◽  
Vol 55 (11) ◽  
pp. 797
Author(s):  
Je Yeon Lee ◽  
Ga Young Yang ◽  
So Yeon Park ◽  
Ki-Sook Hong ◽  
Se Jin Oh ◽  
...  
Keyword(s):  
Growth Factor ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Placental Growth Factor
Sign in / Sign up

Export Citation Format

Share Document